Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:LPS 18:1(9Z)/0:0)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST003521 AN005783 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003213 AN005269 The central role of creatine and polyamines in fetal growth restriction Placenta Human Placenta disease University of Udine LC-MS
ST003053 AN005007 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST002094 AN003420 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic LC-MS
ST002094 AN003422 Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) Feces Human Irritable bowel syndrome Mayo Clinic LC-MS
ST002066 AN003366 Glutaminase inhibition impairs CD8 T cell activation in STK11/Lkb1 deficient lung cancer Lung Mouse Cancer Walter and Eliza Hall Institute of Medical Research LC-MS
ST001796 AN002918 Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib Mesenteric lymph Mouse Diabetes Monash Institute of Pharmaceutical Sciences LC-MS
ST001795 AN002916 Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) Mesenteric lymph Mouse Obesity Monash Institute of Pharmaceutical Sciences LC-MS
ST001304 AN002173 Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii Fibroblast cells Toxoplasma gondii Parasitic infection Monash University LC-MS
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001205 AN002007 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001175 AN001951 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000624 AN000956 Human trabecular meshowrk phospholipid profiles of control and glaucomatous eyes Eye tissue Human Eye disease University of Miami MS(Dir. Inf.)
ST000616 AN000945 Human Aqueous Humor Phospholipids in Control and Glaucomatous eyes Eye tissue Human Eye disease University of Miami MS(Dir. Inf.)
ST000580 AN000891 DBA2J Phosphatidylethserine Analysis Eye tissue Mouse Eye disease University of Miami MS(Dir. Inf.)
ST000546 AN000833 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash University LC-MS
ST000414 AN000656 Metabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action Cells Plasmodium falciparum Malaria Monash Institute of Pharmaceutical Sciences LC-MS
ST000248 AN000392 Metabolic heterogeneity in Glioblastoma Glioma cells Human Cancer University of Florida LC-MS
  logo